Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2011 Apr 15;17(8):2071-3. doi: 10.1158/1078-0432.CCR-11-0211. Epub 2011 Mar 2.

Targeting the Hedgehog pathway in cancer: can the spines be smoothened?

Author information

1
Princess Margaret Hospital, Ontario Cancer Institute, University of Toronto, Toronto, Canada.

Abstract

Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.

PMID:
21367749
DOI:
10.1158/1078-0432.CCR-11-0211
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center